Home >Research Discovery>Discovery Biology and Core Support Groups

Discovery Chemistry

Introduction of group leader

Kaapjoo Park, Ph.D.
Doctorate: Brown University, USA (1997)
Post-Doctorate: Texas A&M University, USA (1997-1998)
Research Scientist, Duke University, USA (1998-2001)
Project Leader, Pfizer Inc. USA (2001-2010)
Director, Yuhan Corp. S. Korea (2010-2015)
Instructor, Kyunghee University, S. Korea (2015)
CTO, Natural F&P (2016)
Hankuk University of Foreign Studies, S. Korea, Instructor (2016-2017)
Director, IPK Business Development & Medicinal Chemistry (2017-present)

Office phone: +82-31-8018-8009
Email: kaapjoo.park at ip-korea.org
Office location: R5.03

Research Interests

The Discovery Chemistry group focuses on the optimization of compounds, which are identified through primary screening as being effective against target diseases. The optimization process is a multidisciplinary task to improve potential of becoming a new drug by optimizing biological activity, selectivity, physicochemical properties, in vivo properties and safety. Within the context of cell-based assays, optimization to create drug candidates is accelerated by eliminating unsatisfactory compounds, which have low cell permeability, as well as cytotoxicity, while evaluating biological activity. Additionally, integration of evaluating in vivo properties and toxicity make our drug discovery process faster and more efficient. Thereby qualified advanced molecules or preclinical candidates are created through lead optimization and our ample experience and creativity leads to successful research results. The Discovery Chemistry group’s area of expertise lies in infectious diseases like tuberculosis, hepatitis C, influenza, etc.

Our areas of activity include : 

• Advancing and accelerating the optimization on drug discovery program
• Developing probe molecules for identifying target and understanding the in vivo mechanism of drug candidates
• Developing tool compounds for monitoring drug localization in either the cell or living animal 
• Providing open-analysis service and support to academia and pharmaceutical companies through collaboration as well as giving access to IPK’s well-equipped infrastructure
 

View Publications